公开(公告)号：WO1994012618A1

公开(公告)日：1994-06-09

申请号：PCT/US1993011541

申请日：1993-11-30

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： MASSACHUSETTS INSTITUTE OF TECHNOLOGY ,  UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  SASISEKHARAN, Ramnath ,  LOHSE, Daniel, L. ,  COONEY, Charles, L. ,  LINHARDT, Robert, J. ,  LANGER, Robert, S.

IPC: C12N09/00

CPC classification number: C12N9/88 ,  Y10S435/822 ,  Y10S435/85

Abstract: A single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity is disclosed herein. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. Monoclonal antibodies to the three heparinases are also described and are useful for detection, isolation and characterization of the heparinases.

Abstract translation: 本文公开了将来自肝素肝素的所有三种肝素裂解酶同时纯化到表观均一性的单一可再现方案。 已经确定了肝素裂解酶的动力学性质以及优化其活性和稳定性的条件。 还描述了三种肝素酶的单克隆抗体，并且其可用于肝素酶的检测，分离和表征。

公开(公告)号：WO2005089365A2

公开(公告)日：2005-09-29

申请号：PCT/US2005/008706

申请日：2005-03-16

Applicant: THE GENERAL HOSPITAL CORPORATION ,  THE UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  HALES, Charles, A. ,  GARG, Hari ,  YU, Lunyin ,  LINHARDT, Robert, J.

Inventor： HALES, Charles, A. ,  GARG, Hari ,  YU, Lunyin ,  LINHARDT, Robert, J.

IPC: A61K31/727

CPC classification number: A61K31/727 ,  C08B37/0075

Abstract: This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of 0-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors); (2) benign and malignant cells of other proliferative disease in which aberrant cellular proliferation occurs; (3) aberrant smooth muscle cell proliferation, such as might occur following treatment for coronary atherosclerosis such as angioplasty or the insertion of a stent into an occluded vessel.

Abstract translation: 本发明提供通过施用有效量的O-酰化肝素衍生物来抑制或预防细胞异常生长的方法，包括转化细胞。 细胞的异常生长指独立于正常调节机制的细胞生长（例如接触抑制的丧失）。 这包括异常生长：（1）肿瘤细胞（肿瘤）; （2）发生异常细胞增殖的其他增殖性疾病的良性和恶性细胞; （3）异常平滑肌细胞增殖，例如在治疗冠状动脉粥样硬化如血管成形术或将支架插入闭塞血管之后可能发生。

公开(公告)号：WO2004075848A2

公开(公告)日：2004-09-10

申请号：PCT/US2004/005402

申请日：2004-02-23

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  LINHARDT, Robert, J. ,  KIM, Yeong, Shik

Inventor： LINHARDT, Robert, J. ,  KIM, Yeong, Shik

IPC: A61K

CPC classification number: A61K31/715 ,  A61K31/737

Abstract: The present invention provides pharmaceutical compositions for the treatment of cancer and inhibiting an increase in the volume or mass of a tumor, and methods for the treatment of cancer and inhibiting an increase in the volume or mass of a tumor.

Abstract translation: 本发明提供了用于治疗癌症并抑制肿瘤体积或质量增加的药物组合物，以及用于治疗癌症和抑制肿瘤体积或质量增加的方法。

公开(公告)号：WO1994014823A1

公开(公告)日：1994-07-07

申请号：PCT/US1993012556

申请日：1993-12-20

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  DORDICK, Jonathan, S. ,  MARTIN, Brett, D. ,  LINHARDT, Robert, J.

IPC: C07H01/00

CPC classification number: C07H13/04 ,  C07H15/04 ,  C08B37/00 ,  C08F220/30 ,  C08F290/10 ,  C12P7/62 ,  C12P19/00 ,  C12P19/02 ,  C12P19/04 ,  C12P19/44

Abstract: Sugar-containing poly(acrylate)-based hydrogels and methods of preparing these hydrogels are disclosed. Poly(sugar acrylate)s are chemeoenzymatically prepared and crosslinked to form hydrogels, which are water absorbant.

Abstract translation: 公开了含糖的聚（丙烯酸酯）基水凝胶和制备这些水凝胶的方法。 聚（糖丙烯酸酯）被化学制备和交联以形成水凝胶，其是吸水剂。

公开(公告)号：WO1994026759A1

公开(公告)日：1994-11-24

申请号：PCT/US1994005327

申请日：1994-05-13

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  BEVILACQUA, Michael, P. ,  NELSON, Richard, M. ,  LINHARDT, Robert, J.

IPC: C07H19/00

CPC classification number: A61K31/715 ,  A61K31/70 ,  C07H3/06 ,  C07H11/00

Abstract: Selectin receptor binding is modulated by a method which utilizes heparin-like oligosaccharides. The figure shows a schematic drawing of the molecules involved in leukocyte adhesion to the vessel wall.

Abstract translation: 选择素受体结合受利用肝素寡糖的方法调节。 该图示出了涉及白细胞粘附到血管壁的分子的示意图。

公开(公告)号：WO1992002816A1

公开(公告)日：1992-02-20

申请号：PCT/US1991005215

申请日：1991-07-23

Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Inventor： UNIVERSITY OF IOWA RESEARCH FOUNDATION ,  LINHARDT, Robert, J. ,  LEE, Kyung-Bok ,  AL-HAKIM, Ali ,  LOGANATHAN, Duraikkannu

IPC: G01N33/52

CPC classification number: G01N33/52 ,  C12Q1/34 ,  G01N2333/924 ,  Y10T436/143333

Abstract: The electrophoretic isolation and monosaccharide sequence determination of a neutral or weakly acidic oligosaccharide species of interest are disclosed. A labeling compound and a charged group are coupled to the reducing end of the species of interest, thereby facilitating electrophoretic separation and detection of the separated species. The resolved species of interest can then be recovered from the electrophoretic medium, for example, by electrophoretic transfer to a charged solid support. Following isolation, monosaccharide units can be cleaved successively from the non-reducing end of the species of interest to reveal the monosaccharide sequence. The identity of each monosaccharide unit is determined by correlating cleavage data with known exoglycosidase specificites.